Cefaclor–Ceftriaxone Cross-Reactivity in Cephalosporin Allergy
Direct evidence specifically quantifying cross-reactivity from cefaclor allergy to ceftriaxone is limited in the available literature. [1]
Cephalosporin cross-reactivity patterns appear to be driven primarily by IgE recognition of side-chain determinants, so reactions to one cephalosporin do not necessarily predict reactions to another with a dissimilar side chain. [2]
Evidence for Side-Chain–Dependent Cross-Reactivity
A prospective study assessing cross-reactivity in cephalosporin-allergic populations found that clinically assessed immediate hypersensitivity is often related to drug-specific patterns assessed with skin testing and provocation, with only a minority of test-negative patients reacting on challenge. [1]
In a prospective evaluation of patients with IgE-mediated penicillin hypersensitivity, all patients who had negative testing for selected cephalosporins tolerated ceftriaxone on challenge. [2]
In a pediatric cohort study evaluating cross-reactivity between beta-lactams, patients with selective ceftriaxone allergy tolerated other cephalosporins with dissimilar side chains, including cefaclor. [3]
Clinical Implication for Cefaclor-Allergic Patients
Because cefaclor and ceftriaxone do not share identical side-chain determinants, cross-reactivity is expected to be uncommon when a cefaclor reaction is isolated and when testing supports tolerance of ceftriaxone. [2]
Definitive assessment of tolerance for ceftriaxone in a cefaclor-allergic patient requires an allergy evaluation using cephalosporin-directed skin testing and, when appropriate, a supervised graded challenge. [1]
Practical Safety Considerations
Rechallenge in patients with histories of immediate hypersensitivity should be performed under specialist supervision due to the risk of IgE-mediated reactions in those with positive or inconclusive testing. [1]
When skin testing is negative, supervised provocation has demonstrated that a substantial proportion of cephalosporin-labeled patients can tolerate the implicated cephalosporins, supporting diagnostic clarification and avoidance of unnecessary broad avoidance. [1]
Decision Framework for Ceftriaxone Use
- Allergy evaluation should be prioritized to determine whether the cefaclor history represents IgE-mediated hypersensitivity to a specific determinant. [1]
- Ceftriaxone administration should be based on the results of cephalosporin-directed testing and, when indicated, supervised challenge. [1]
- If testing supports low risk, tolerance of ceftriaxone has been demonstrated in prospective cohorts when prior testing was negative. [2]
What Cannot Be Concluded
The existing prospective studies do not provide a precise cefaclor-to-ceftriaxone cross-reactivity percentage for patients labeled as cefaclor-allergic. [1]
The literature supports side-chain–dependent cross-reactivity, but the exact risk for an individual cefaclor-allergic patient cannot be inferred from studies focused on other source populations. [2]
References Supporting the Most Direct Evidence
- In immediate cephalosporin reaction cohorts, most patients had test-supported immediate hypersensitivity, but a small subset reacted on challenge after negative testing. [1]
- In studies emphasizing side-chain determinants, tolerance of ceftriaxone (in penicillin-allergic patients with negative testing) and tolerance of cefaclor (in selective ceftriaxone allergy with dissimilar side chains) have both been observed. [2] [3]
Final Determination
Cefaclor allergy does not automatically imply ceftriaxone cross-reactivity, and cross-reactivity is expected to be low when side chains differ and ceftriaxone tolerance is supported by negative evaluation and supervised challenge when indicated. [2] [3]